Physician profile
Neelima Kothari
NPI 1578594735
$5,711.19
in general payments reported to CMS, 2019-2025
34 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $282 · 2021: $397 · 2022: $447 · 2023: $889 · 2024: $1,635 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,145.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $641.31 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $568.51 | 2022-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.38 | 2019-2025 | Ofev, Combivent Respimat, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $523.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $365.76 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Grifols USA, LLC | $323.55 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Pulmonx Corporation | $212.65 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Ani Pharmaceuticals, INC. | $159.43 | 2024-2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $156.31 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $146.07 | 2024-2025 | Acthar |
| Axsome Therapeutics, INC. | $137.17 | 2022-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $80.67 | 2022-2025 | Dupixent |
| Insmed, INC. | $76.34 | 2019-2023 | Arikayce |
| Genzyme Corporation | $70.21 | 2023-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.46 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $57.12 | 2023-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $49.98 | 2025 | Opsumit |
| Amgen INC. | $49.56 | 2023-2024 | Tezspire |
| Mylan Specialty L.P. | $37.44 | 2019 | |
| United Therapeutics Corporation | $33.67 | 2024 | Tyvaso |
| Resmed Corp | $28.44 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.90 | 2025 | |
| Fisher & Paykel Healthcare INC | $24.14 | 2024 | Fisher & Paykel Healthcare |
| Viatris Specialty LLC | $23.74 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $21.85 | 2025 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $21.66 | 2019 | |
| Abbvie INC. | $19.84 | 2023 | |
| Allergan, INC. | $17.75 | 2020 | |
| Baxter Healthcare | $17.47 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $17.31 | 2019 | |
| Merck Sharp & Dohme LLC | $15.06 | 2024 | Capvaxive |
| Phadia US INC. | $14.42 | 2019 | |
| Inogen, INC. | $9.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neelima Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.